Cite
Long‐term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first‐line biologics.
MLA
Inokuchi, Toshihiro, et al. “Long‐term Outcomes of Patients with Crohn’s Disease Who Received Infliximab or Adalimumab as the First‐line Biologics.” Journal of Gastroenterology & Hepatology, vol. 34, no. 8, Aug. 2019, pp. 1329–36. EBSCOhost, https://doi.org/10.1111/jgh.14624.
APA
Inokuchi, T., Takahashi, S., Hiraoka, S., Toyokawa, T., Takagi, S., Takemoto, K., Miyaike, J., Fujimoto, T., Higashi, R., Morito, Y., Nawa, T., Suzuki, S., Nishimura, M., Inoue, M., Kato, J., & Okada, H. (2019). Long‐term outcomes of patients with Crohn’s disease who received infliximab or adalimumab as the first‐line biologics. Journal of Gastroenterology & Hepatology, 34(8), 1329–1336. https://doi.org/10.1111/jgh.14624
Chicago
Inokuchi, Toshihiro, Sakuma Takahashi, Sakiko Hiraoka, Tatsuya Toyokawa, Shinjiro Takagi, Koji Takemoto, Jiro Miyaike, et al. 2019. “Long‐term Outcomes of Patients with Crohn’s Disease Who Received Infliximab or Adalimumab as the First‐line Biologics.” Journal of Gastroenterology & Hepatology 34 (8): 1329–36. doi:10.1111/jgh.14624.